Pharm 30 Part I Flashcards Preview

PBL Pharm Block 3 > Pharm 30 Part I > Flashcards

Flashcards in Pharm 30 Part I Deck (41)
Loading flashcards...
1

alpha-glucosidase inhibitors (3)

acarbose, migitol, voglibose

2

Prandial Bolus Insulins (4)

"LAGeR" Insulin Lispro, Insulin aspart, Insulin glulisine, Regular Insulin

3

Basal " long acting " insulins (3)

NPH insulin, insulin glargine, Insulin detemir

4

First generation (4): Inhibit the beta-cell K+/ATP channel at the SUR1 subunit; thereby stimulating insulin release from pancreatic beta-cells and increasing circulating insulin to levels sufficient to overcome insulin resistance

TACT
- Tolbulamide, acetohexamide, chlorpropamide, tolazamide

5

Second generation (5): Inhibit the beta-cell K+/ATP channel at the SUR1 subunit; thereby stimulating insulin release from pancreatic beta-cells and increasing circulating insulin to levels sufficient to overcome insulin resistance

G's
- Glimepiride, Glipizide, Glibenclamide, Gliclazide, Gliquidone

6

Inhibit the beta-cell K+/ATP channel at the SUR1 subunit; thereby stimulating insulin release from pancreatic beta-cells and increasing circulating insulin to levels sufficient to overcome insulin resistance (2)

Nateglinide, Repaglinide

7

Activates AMPK to block synthesis of fatty acids and to inhibit hepatic gluconeogenesis and glycogenolysis; increases insulin receptor activity and metabolic responsiveness in liver and skeletal muscle.

Metformin

8

Acts on receptors in the CNS to slow gastric emptying, reduce postprandial glucagon and glucose release, and promote satiety.

Pramlintide

9

Act on Glucagon-like peptide-1 receptor to enhance glucose-dependent insulin secretion, inhibit glucagon secretion, delay gastric emptying, and decrease appetite.

"El" Exenatide, Liraglutide

10

Prolongs GLP-1 activity to enhance glucose-dependent insulin secretion, inhibit glucagon secretion, delay gastric emptying, and decrease appetite.

Sit-Sax (instead of the sitaur) Sitagliptin, Saxagliptin

11

Bind and stimulates the nuclear hormone receptor peroxisome proliferator-activated receptor-gamma (PPARgamma), thereby increasing insulin sensitivity in adipose tissue, liver, and muscle

Rosiglitazone, Pioglitazone
- GLITAZONES

12

Inhibits GHRH release

Octreotide

13

MOA: Bind avidly to intestinal brush border alpha glucosidase enzymes, slowing breakdown and absorption of dietary carbohydrates such as dextrin, and disaccharides

alpha glucosidase inhibitors (acarbose, migitol, voglibose)

14

Contraindications Include cirrhosis, DKA, digestive problems, IBD, and Bowel obstruction

alpha-glucosidases

15

hypoglycemia is the sole CI for

Exogenous insulin

16

DKA is the sole CI for

Sulfonylureas

17

DKA + Type 1 diabetes are the CIs for

Meglitinides

18

Contraindications are metabolic acidosis, Hepatic disease, Renal impairment, Respiratory distress, Alcohol abuse, Septicemia, Heart failure

Metformin

19

What may result in a patient on Metformin that has received iodinated contrast media if acute alteration of renal function is an underlying issue ?

Lactic Acidosis

20

Hypoglycemia + Gastroparesis CI for

Pramlintide

21

ype 1 dm + DKA CI for

Incretins (GLP-1 analogues and DPP4 inhibitors

22

Heart failure is the sole CI for

TZDs (GLITAZONES)

23

Patient with a pheochromocytoma cannot receive

exogenous glucagon

24

Type 2 dm and polycystic ovarian syndrom are indicated for use of

Metformin

25

Both Type 1 and type 2 diabetes mellitus can receive

Pramlinitide

26

Hypoglycemia + Malignant hypertension(off-label) are both indications to use

Diazoxide

27

Hypoglycemia + intestinal relaxant before radiography of GI indicated with

Exogenous glucagon

28

Hypoglycemia, Rash, diarrhea, nausea, and dizziness are ADRs of

Meglitinides

29

Nausea is the only ADR of

Pramlintide

30

Hypoglycemia nausea vomitting diarrhea nervousness , dizziness and HEADACHE are ADRs of

GLP-1 analogues ("EL)